Skip to main content

Table 3 Number of subjects from different cohorts for each modality by diagnosis

From: The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics

Cohort Diagnosis Clinical data Plasma DNA MRI CSF
Amsterdam NC 30 29 26 30 30
MCI 82 80 68 82 82
AD-type dementia 60 60 53 60 60
Antwerp MCI 103 100 101 50 103
AD-type dementia 46 47 46 0 46
DESCRIPA NC 12 12 8 5 12
MCI 17 17 12 9 17
EDAR NC 48 47 42 14 47
MCI 77 75 65 24 75
AD-type dementia 79 78 69 19 76
GAP NC 40 40 40 38 40
Gothenburg NC 49 48 48
MCI 46 44 46
IDIBAPS NC 76 77 40
MCI 27 27 14
AD-type dementia 17 16 14
Lausanne NC 12 12 12 12 12
MCI 28 28 28 27 28
Leuven NC 180 163 168 179
PharmaCog MCI 147 144 146 147 147
Sant Pau NC 45 45 45
Total NC 492 473 341 366 141
MCI 527 515 420 399 452
AD-type dementia 202 201 168 100 182
Overall 1221 1189 929 865 775
  1. CSF cerebrospinal fluid, DESCRIPA development of screening guidelines and clinical criteria for predementia Alzheimer's disease, EDAR beta amyloid oligomers in the early diagnosis of AD and as a marker for treatment reponse, GAP gipuzkoa Alzheimer project, IDIBAPS institut d'investigacions biomèdiques August Pi i Sunyer, MCI mild cognitive impairment, MRI magnetic resonance imaging, NC normal cognition